thoughts on these estimates, before EPS results? NASDAQ:KLXE, NASDAQ:PTGX, NASDAQ:LYRA, NASDAQ:MDXG

0
114

KLX ENERGY SERVICES (NASDAQ:KLXE) EARNINGS INFORMATION (NASDAQ:KLXE)

KLX Energy Services last issued its quarterly earnings data on December 6th, 2020. The reported ($3.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $3.35. The business earned $70.90 million during the quarter. KLX Energy Services has generated ($21.60) earnings per share over the last year. KLX Energy Services has confirmed that its next quarterly earnings report will be published on Wednesday, April 14th, 2021. KLX Energy Services will be holding an earnings conference call on Wednesday, April 14th. Interested parties can register for or listen to the call using this link.

IS KLX ENERGY SERVICES A BUY RIGHT NOW? (NASDAQ:KLXE)

4 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for KLX Energy Services in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” KLX Energy Services stock.
KLX Energy Services

PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) EARNINGS INFORMATION (NASDAQ:PTGX)

Protagonist Therapeutics last posted its earnings data on March 10th, 2021. The reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.48). Protagonist Therapeutics has generated ($2.98) earnings per share over the last year. Protagonist Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, May 5th, 2021 based off prior year’s report dates.

IS PROTAGONIST THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:PTGX)

7 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Protagonist Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Protagonist Therapeutics stock.
Protagonist Therapeutics

LYRA THERAPEUTICS (NASDAQ:LYRA) EARNINGS INFORMATION (NASDAQ:LYRA)

Lyra Therapeutics last released its earnings results on March 8th, 2021. The reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.10. Lyra Therapeutics has generated $0.00 earnings per share over the last year. Lyra Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 27th, 2021 based off prior year’s report dates.

IS LYRA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:LYRA)

4 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Lyra Therapeutics stock.
Lyra Therapeutics

MIMEDX GROUP (NASDAQ:MDXG) EARNINGS INFORMATION (NASDAQ:MDXG)

MiMedx Group last released its quarterly earnings data on March 9th, 2021. The reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.12. MiMedx Group has generated $0.00 earnings per share over the last year. MiMedx Group has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, July 5th, 2021 based off prior year’s report dates.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN MIMEDX GROUP? (NASDAQ:MDXG)

Wall Street analysts have given MiMedx Group a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MiMedx Group wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat’s top stock picks here.